SCHEMBL9890801

SCHEMBL9890801

CC(C(N)=O)c1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 1/20 0.48
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 2/20 0.45
CNR2 P34972 2/20 0.44
APP P05067 1/20 0.44
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
SLC9A1 P19634 3/20 0.41
PTGS2 P35354 1/20 0.40
RORB Q92753 2/20 0.40
RORC P51449 1/20 0.40
PARP1 P09874 1/20 0.40
NUDT1 P36639 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890685 0.87 PTGS2 (0.53) CXCL8HSP90AA1HSP90AB1APPCHRM1
SCHEMBL11133836 0.84 AKR1C3 (0.47) CXCL8PTGS2PARP1
SCHEMBL9890803 0.84 CHRM1 (0.46) HSP90AA1HSP90AB1CNR2CHRM1CHRM3
SCHEMBL2391809 0.82 BCAT2 (0.48) CXCL8CHRM3PTGS2
SCHEMBL2391830 0.82 HSP90AA1 (0.45) HSP90AA1HSP90AB1CNR2CHRM1CHRM3
SCHEMBL2393565 0.82 PTGS2 (0.43) CXCL8SLC9A1PTGS2PARP1MAOB
SCHEMBL2393363 0.82 RORC (0.43) HSP90AA1HSP90AB1CNR2CHRM1CHRM3
SCHEMBL2389641 0.75 HSP90AA1 (0.47) HSP90AA1HSP90AB1CHRM1CHRM3PTGS2
SCHEMBL9890709 0.74 HSP90AA1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3RORB
SCHEMBL9890688 0.74 HSP90AA1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3RORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885HSP90AA1 1699/4885HSP90AB1 2118/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885HSP90AA1 1699/4885HSP90AB1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.